Rem-L needed Yesterday, page-7

First 7 Last

Share
Profile

Follow
Wilba32

7,005 Posts.

1541

25/09/21

10:29

Post #: 56342745
Share

Originally posted by ton9031: ↑

Agreed. The CHF is the one that is hard to work out. On one hand there is a reduction in death and life threatening incidents like stroke and heart attack which has an immediate benifit but there is also the halt on disease progression which need longer trail time to demonstrate.

CLBP shows an immediate reduction on opioid dependence which could only need 12 month trail and has a system to utilise in surgcentre clinics for recruitment and observations if not seen as a conflicting resource.

other then paediatric AGVHD u.s. revenue with some small off label revenue to possibly 2hcy22 we still need to partner for the bigger indication of CHF.

I can't see significant share price increases until both CLBP trail started with achievable p.e. and CHF partnering and trail established.

still alot of potential but need more information which could be known by the end of the year.

your thoughts?

Expand

I’m holding & buying when there is spare $$$ (not any spare of late ).

IMO, everything is still a goer! Govt wheels move so slow. Plus, there is no precedent for such medical use,,,, so let’s just check those wheels one more time! We are jumping a bar so high but once cleared our competitors will only be able to dream for years to come.

It’ll happen when it happens… and when it happens, the wait will be worth it!

but I’m biased… I invested because of the science & the company!

MSB Price at posting: $1.72 Sentiment: Buy Disclosure: Held
10 Upvote

0 Great analysis

Reply

Top Stories

Aussie inflation seemingly hit a 3 year low. So why's the ASX200 red?

Palladium's the newest geopolitical hot commodity. But ASX exposure is limited

Bitcoin hits fresh record as instos pile into BTC ETFs – and Trump helps, too

Making money: How many microcaps should be in an investor's portfolio?

The Altcoin Landscape (Part 1): Key alternative cryptocurrencies to watch